Stamulumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | myostatin |
| Clinical data | |
| Routes of administration | injection only |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6330H9748N1672O1668S48 |
| Molar mass | 137500.53 g·mol−1 |
| (what is this?) (verify) | |
Stamulumab (MYO-029[1]) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy (MD). Stamulumab was formulated and tested by Wyeth in Collegeville, Pennsylvania.[2] Myostatin is a protein that inhibits the growth of muscle tissue, stamulumab is a recombinant human antibody designed to bind to and inhibit the activity of myostatin.[3]
Stamulumab is a G1 immunoglobulin antibody which binds to myostatin and prevents it from binding to its target site, thus inhibiting the growth-limiting action of myostatin on muscle tissue. Research completed in 2002 found that Stamulumab might one day prove to be an effective treatment for Duchenne muscular dystrophy.[4]
- ^ Wyeth Product Pipeline Archived 2007-05-09 at the Wayback Machine, Wyeth, Website accessed April 22, 2007
- ^ "Study Evaluating MYO-029 in Adult Muscular Dystrophy". clinicaltrials.gov. 24 June 2007. Retrieved 2023-02-19.
- ^ "Wyeth Initiates Clinical Trial with Investigational Muscular Dystrophy Therapy MYO-029". www.medicalnewstoday.com (Press release). 28 February 2005. Archived from the original on 15 March 2005. Retrieved 2023-02-19.
- ^ "Blocking Myostatin Proves Beneficial in Mice with DMD". MDA Research News. 27 November 2002. Archived from the original on 22 December 2002. Retrieved 2023-02-19.